Zheng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zheng Li has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
Haogui Zhao
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China
10 shared publicationsLan Zhang
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China
9 shared publicationsMumei Chen
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China
8 shared publicationsQingnuan Li
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China
8 shared publicationsYiyun Geng
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China
7 shared publications- Lan Zhang
Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, China
6 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 11 (1)
Preliminary biological evaluation of a [177Lu]Lu-labeled peptide targeting Nectin-4
Despite the clinical implementation of Nectin-4-targeted antibody-drug conjugates (ADCs) and radioligand therapies (RLTs), their therapeutic window is often restricted by systemic toxicities and the emergence of drug resistance. To circumvent these limitations, we developed [177Lu]Lu-DOTA-AC-SP, a novel peptide-based radiopharmaceutical specifically engineered for the targeted treatment of Nectin-4-expressing malignancies. The synthesis of [177Lu]Lu-DOTA-AC-SP was achieved with high radiochemical purity and excellent stability in vitro. Pharmacokinetic evaluations revealed a favorable profile characterized by high binding affinity and rapid systemic clearance. In vivo biodistribution studies demonstrated significant tumor accumulation and prolonged retention, resulting in superior target-to-background ratios. Furthermore, [177Lu]Lu-DOTA-AC-SP exhibited robust anti-tumor efficacy in Nectin-4-positive models, maintaining an excellent safety profile with minimal off-target effects. These findings characterize [177Lu]Lu-DOTA-AC-SP as a potent and safe therapeutic candidate for Nectin-4-positive tumors. Its favorable pharmacokinetic properties and significant therapeutic index support its potential clinical translation as a next-generation treatment for urothelial carcinoma (UC).
- 30 March 2026
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 11 (1)
Open AccessPreliminary biological evaluation of a [177Lu]Lu-labeled peptide targeting Nectin-4
Despite the clinical implementation of Nectin-4-targeted antibody-drug conjugates (ADCs) and radioligand therapies (RLTs), their therapeutic window is often restricted by systemic toxicities and the emergence of drug resistance. To circumvent these limitations, we developed [177Lu]Lu-DOTA-AC-SP, a novel peptide-based radiopharmaceutical specifically engineered for the targeted treatment of Nectin-4-expressing malignancies. The synthesis of [177Lu]Lu-DOTA-AC-SP was achieved with high radiochemical purity and excellent stability in vitro. Pharmacokinetic evaluations revealed a favorable profile characterized by high binding affinity and rapid systemic clearance. In vivo biodistribution studies demonstrated significant tumor accumulation and prolonged retention, resulting in superior target-to-background ratios. Furthermore, [177Lu]Lu-DOTA-AC-SP exhibited robust anti-tumor efficacy in Nectin-4-positive models, maintaining an excellent safety profile with minimal off-target effects. These findings characterize [177Lu]Lu-DOTA-AC-SP as a potent and safe therapeutic candidate for Nectin-4-positive tumors. Its favorable pharmacokinetic properties and significant therapeutic index support its potential clinical translation as a next-generation treatment for urothelial carcinoma (UC).
- 23 March 2026
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 335 (4) , 2987-2998
Preparation and preliminary biological evaluation of [131I]I-yg-15 peptide
- 23 March 2026
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 335 (4) , 2987-2998
Preparation and preliminary biological evaluation of [131I]I-yg-15 peptide
- 8 April 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (5) , 2535-2544
Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study
Radiopharmaceuticals are a promising therapeutic strategy for tumors with less reduced resistance and minimal side effects. In our previous study, we radiolabeled the monoclonal antibody zolbetuximab, which targets CLDN18.2, with 125I, and the labeled compound showed favorable tumor targeting and retention. In this research article, [131I]I-zolbetuximab was prepared to investigate its therapeutic effect on gastric cancer using in vitro and in vivo studies. The zolbetuximab was radiolabeled with 131I using the Iodogen method. The uptake mechanism of [131I]I-zolbetuximab was investigated through an endocytosis experiment using MKN45-CLDN18.2 and MKN45 cells. The safety assessment of [131I]I-zolbetuximab was conducted in normal mice using hematoxylin/eosin (H&E) staining. The tumor uptake, biodistribution, and therapeutic efficacy of [131I]I-zolbetuximab were evaluated in nude mice bearing MKN45-CLDN18.2 tumors, while the hematological analysis, immunohistochemistry, Western blotting (WB), immunofluorescence, and H&E assays were used to further assess the treatment response and toxicity. [131I]I-Zolbetuximab exhibited a high labeling efficiency of (96.05 ± 0.23)%, a specific activity of 1.75 × 102 GBq/μmol, and good in vitro stability. The binding of [131I]I-zolbetuximab to the membrane surface receptors of MKN45-CLDN18.2 cells resulted in significant tumor uptake, retention, and favorable biodistribution in CLDN18.2-positive tumor-bearing nude mice. Safety assessments, including H&E staining, indicated no significant damage to normal mouse organs caused by the labeled compounds. In a therapeutic study involving MKN45-CLDN18.2 tumor-bearing nude mice, increasing drug dose led to notable enhancements in therapeutic efficacy and survival rates. H&E staining of mouse organs at the end of treatment showed no significant toxicity was observed across all dose groups throughout the treatment period. Furthermore, immunohistochemistry, immunoblotting, and immunofluorescence analyses conducted on mouse tumors at the treatment end point demonstrated a reduction in CLDN18.2 expression following treatment. Altogether, [131I]I-zolbetuximab displayed exceptional targeting capability, tumor retention property, significant therapeutic efficacy, and safety. These findings suggest its potential to serve as a targeted radiopharmaceutical for the treatment of CLDN18.2-positive gastric cancer.
- 8 April 2025
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 22 (5) , 2535-2544
Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [131I]I-Zolbetuximab: An In Vitro and In Vivo Study
Radiopharmaceuticals are a promising therapeutic strategy for tumors with less reduced resistance and minimal side effects. In our previous study, we radiolabeled the monoclonal antibody zolbetuximab, which targets CLDN18.2, with 125I, and the labeled compound showed favorable tumor targeting and retention. In this research article, [131I]I-zolbetuximab was prepared to investigate its therapeutic effect on gastric cancer using in vitro and in vivo studies. The zolbetuximab was radiolabeled with 131I using the Iodogen method. The uptake mechanism of [131I]I-zolbetuximab was investigated through an endocytosis experiment using MKN45-CLDN18.2 and MKN45 cells. The safety assessment of [131I]I-zolbetuximab was conducted in normal mice using hematoxylin/eosin (H&E) staining. The tumor uptake, biodistribution, and therapeutic efficacy of [131I]I-zolbetuximab were evaluated in nude mice bearing MKN45-CLDN18.2 tumors, while the hematological analysis, immunohistochemistry, Western blotting (WB), immunofluorescence, and H&E assays were used to further assess the treatment response and toxicity. [131I]I-Zolbetuximab exhibited a high labeling efficiency of (96.05 ± 0.23)%, a specific activity of 1.75 × 102 GBq/μmol, and good in vitro stability. The binding of [131I]I-zolbetuximab to the membrane surface receptors of MKN45-CLDN18.2 cells resulted in significant tumor uptake, retention, and favorable biodistribution in CLDN18.2-positive tumor-bearing nude mice. Safety assessments, including H&E staining, indicated no significant damage to normal mouse organs caused by the labeled compounds. In a therapeutic study involving MKN45-CLDN18.2 tumor-bearing nude mice, increasing drug dose led to notable enhancements in therapeutic efficacy and survival rates. H&E staining of mouse organs at the end of treatment showed no significant toxicity was observed across all dose groups throughout the treatment period. Furthermore, immunohistochemistry, immunoblotting, and immunofluorescence analyses conducted on mouse tumors at the treatment end point demonstrated a reduction in CLDN18.2 expression following treatment. Altogether, [131I]I-zolbetuximab displayed exceptional targeting capability, tumor retention property, significant therapeutic efficacy, and safety. These findings suggest its potential to serve as a targeted radiopharmaceutical for the treatment of CLDN18.2-positive gastric cancer.
- 10 January 2025
- Published by Springer Nature in Nuclear Science and Techniques
- Vol. 36 (2) , 1-9
Ultra-high quality factor and ultra-high accelerating gradient achievements in a 1.3 GHz continuous wave cryomodule
- 10 January 2025
- Published by Springer Nature in Nuclear Science and Techniques
- Vol. 36 (2) , 1-9
Ultra-high quality factor and ultra-high accelerating gradient achievements in a 1.3 GHz continuous wave cryomodule
- 1 July 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (8) , 3838-3847
Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications
Claudin18.2 (CLDN18.2), due to its high expression in various gastric cancer tissues, is considered an optimal target for antitumor drug molecules. In this study, we obtained the labeled compounds of [125I]I-zolbetuximab using the Iodogen method. Under the optimum labeling conditions, the molar activity of [125I]I-zolbetuximab was 1.75 × 102 GBq/μmol, and the labeling efficiency was more than 99%. The labeled compounds exhibited excellent in vitro stability in both phosphate buffer saline (PBS, pH = 7.4) and fetal bovine serum systems (FBS) (radiochemical purity >90% at 72 h). The uptake percentage of [125I]I-zolbetuximab in MKN45-CLDN18.2 cells is 24.69 ± 0.84% after 6 h. The saturation binding assay and specificity assay further demonstrated the high specificity of [125I]I-zolbetuximab for CLDN18.2. The long retention at the tumor site and rapid metabolic clearance at other organ sites of [125I]I-zolbetuximab were observed in small-animal SPECT-CT imaging. The same trend was also observed in the biodistribution study. Due to the excellent targeting ability of zolbetuximab for CLDN18.2, [125I]I-zolbetuximab exhibits strong specific binding and retention with cells and tumors highly expressing CLDN18.2. However, the balance between mAb's longer cycle time in vivo and targeting binding and retention ability should be intensively considered for using this kind of radiopharmaceutical in the diagnosis and treatment of CLDN18.2-positive gastric cancer.
- 1 July 2024
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 21 (8) , 3838-3847
Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications
Claudin18.2 (CLDN18.2), due to its high expression in various gastric cancer tissues, is considered an optimal target for antitumor drug molecules. In this study, we obtained the labeled compounds of [125I]I-zolbetuximab using the Iodogen method. Under the optimum labeling conditions, the molar activity of [125I]I-zolbetuximab was 1.75 × 102 GBq/μmol, and the labeling efficiency was more than 99%. The labeled compounds exhibited excellent in vitro stability in both phosphate buffer saline (PBS, pH = 7.4) and fetal bovine serum systems (FBS) (radiochemical purity >90% at 72 h). The uptake percentage of [125I]I-zolbetuximab in MKN45-CLDN18.2 cells is 24.69 ± 0.84% after 6 h. The saturation binding assay and specificity assay further demonstrated the high specificity of [125I]I-zolbetuximab for CLDN18.2. The long retention at the tumor site and rapid metabolic clearance at other organ sites of [125I]I-zolbetuximab were observed in small-animal SPECT-CT imaging. The same trend was also observed in the biodistribution study. Due to the excellent targeting ability of zolbetuximab for CLDN18.2, [125I]I-zolbetuximab exhibits strong specific binding and retention with cells and tumors highly expressing CLDN18.2. However, the balance between mAb's longer cycle time in vivo and targeting binding and retention ability should be intensively considered for using this kind of radiopharmaceutical in the diagnosis and treatment of CLDN18.2-positive gastric cancer.
- 9 November 2022
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 331 (12) , 5799-5805
Thermal reaction behavior of “red oil” decomposition products with HNO3
- 9 November 2022
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 331 (12) , 5799-5805
Thermal reaction behavior of “red oil” decomposition products with HNO3
- 17 February 2022
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 331 (4) , 1559-1571
The investigation on thermal decomposition of TBP/n-dodecane-HNO3 mixtures
- 17 February 2022
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 331 (4) , 1559-1571
The investigation on thermal decomposition of TBP/n-dodecane-HNO3 mixtures
- 7 February 2020
- Published by Springer Nature in Journal of Sol-Gel Science and Technology
- Vol. 94 (2) , 375-383
The preparation of graphene foam by one-step reduction and air-drying for oil–water separation
- 7 February 2020
- Published by Springer Nature in Journal of Sol-Gel Science and Technology
- Vol. 94 (2) , 375-383
The preparation of graphene foam by one-step reduction and air-drying for oil–water separation
- 9 January 2020
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 323 (3) , 1157-1165
Removal of entrained organic phase from raffinate in spent fuel reprocessing with graphene-based composites
- 9 January 2020
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 323 (3) , 1157-1165
Removal of entrained organic phase from raffinate in spent fuel reprocessing with graphene-based composites
- 1 September 2019
- Published by Elsevier in Applied Surface Science
- Vol. 487, 962-971
Effect of cations on stabilizing graphene oxide membranes in aqueous solutions
- 1 September 2019
- Published by Elsevier in Applied Surface Science
- Vol. 487, 962-971
Effect of cations on stabilizing graphene oxide membranes in aqueous solutions